OMIC

Singular Genomics Systems, Inc. [OMIC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OMIC Stock Summary

Top 10 Correlated ETFs

OMIC


Top 10 Correlated Stocks

OMIC


In the News

09:14 01 Apr 2023 OMIC

Singular Genomics Systems, Inc. (OMIC) Q4 2022 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Matt Sykes - Goldman Sachs Daniel Brennan - Cowen & Co. Operator Greetings, and welcome to the Singular Genomics Systems, Incorporated Fourth Quarter 2022 Earnings Conference Call.[Operator Instructions] Please note, this conference is being recorded.

06:49 01 Apr 2023 OMIC

Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates

Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

04:05 01 Apr 2023 OMIC

Singular Genomics to Report Fourth Quarter 2022 Financial Results on March 2, 2023

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, March 2, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

08:38 01 Apr 2023 OMIC

Singular Genomics: Betting On Expanding Genomics Systems Market

Singular Genomics Systems is a unique opportunity to invest in a commercially-viable startup at the forefront of a rapidly expanding field. The company has adequate funding to maintain its current level of commercialization and sales activity for a few years.

04:05 01 Apr 2023 OMIC

Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

11:49 01 Apr 2023 OMIC

Singular Genomics Systems, Inc. (OMIC) Q3 2022 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Bruce Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tom Stevens - Cowen John Sourbeer - UBS Operator Good day, ladies and gentlemen and welcome to the Singular Genomics Systems, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor, Investor Relations for Singular Genomics.

04:05 01 Apr 2023 OMIC

Singular Genomics to Report Third Quarter 2022 Financial Results on November 7, 2022

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

04:05 01 Apr 2023 OMIC

Singular Genomics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

04:13 01 Apr 2023 OMIC

Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q2 2022 Results - Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder & CEO Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Dan Brennan - Cowen Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Good day, ladies and gentlemen, and welcome to the Singular Genomics Systems, Incorporated Second Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for questions and comments after the presentation.

04:06 01 Apr 2023 OMIC

Singular Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California.

OMIC Financial details

Company Rating
Buy
Market Cap
87.05M
Income
-86.66M
Revenue
765K
Book val./share
3.66
Cash/share
3.44
Dividend
-
Dividend %
-
Employees
269
Optionable
No
Shortable
Yes
Earnings
02 Mar 2023
P/E
-0.99
Forward P/E
-
PEG
0.82
P/S
112.53
P/B
0.33
P/C
0.35
P/FCF
-1.33
Quick Ratio
17.39
Current Ratio
19.01
Debt / Equity
0.26
LT Debt / Equity
0.2
-
-
EPS (TTM)
-1.21
EPS next Y
-
EPS next Q
-
EPS this Y
-7.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.09%
-
-
-
-
SMA20
-42.51%
SMA50
-46.4%
SMA100
-51.82%
Inst Own
52.21%
Inst Trans
-4.61%
ROA
-26%
ROE
-29%
ROC
-0.28%
Gross Margin
-3%
Oper. Margin
-11623%
Profit Margin
-11328%
Payout
-
Shs Outstand
71.94M
Shs Float
42.28M
-
-
-
-
Target Price
-
52W Range
1.07-6.62
52W High
-79.83%
52W Low
+21%
RSI
35.47
Rel Volume
1.54
Avg Volume
136.91K
Volume
210.8K
Perf Week
-3.59%
Perf Month
-50.21%
Perf Quarter
-50.21%
Perf Half Y
-55.51%
-
-
-
-
Beta
-
-
-
Volatility
0.03%, 0.42%
Prev Close
4.31%
Price
1.21
Change
1.68%

OMIC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000.01
Net income per share
-0.25-0.57-1.38-1.28
Operating cash flow per share
-0.23-0.50-1.22
Free cash flow per share
-0.25-0.530-1.31
Cash per share
0.940.544.733.44
Book value per share
-0.5-1.044.693.66
Tangible book value per share
-0.5-1.044.693.66
Share holders equity per share
-0.5-1.044.693.66
Interest debt per share
0.050.20.010.84
Market cap
1.27B1.27B829.1M143.01M
Enterprise value
1.27B1.27B637.96M127.59M
P/E ratio
-103.1-45.47-8.39-1.57
Price to sales ratio
000186.94
POCF ratio
-111.47-51.080-1.64
PFCF ratio
-104.16-48.40-1.54
P/B Ratio
-51.39-24.652.470.55
PTB ratio
-51.39-24.652.470.55
EV to sales
000166.78
Enterprise value over EBITDA
-106.01-47.7-6.51-1.52
EV to operating cash flow
-111.2-50.990-1.46
EV to free cash flow
-103.9-48.310-1.37
Earnings yield
-0.01-0.02-0.12-0.64
Free cash flow yield
-0.01-0.020-0.65
Debt to equity
-2.95-1.590.060.26
Debt to assets
1.512.690.050.21
Net debt to EBITDA
0.260.091.950.18
Current ratio
41.787.4751.5719.01
Interest coverage
-751.18-38.35-72.43-122.53
Income quality
0.920.8900.96
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
00060.39
Intangibles to total assets
0000
Capex to operating cash flow
0.070.0600.07
Capex to revenue
000-7.87
Capex to depreciation
-2.29-2.160-1
Stock based compensation to revenue
00017.87
Graham number
1.683.6412.0510.25
ROIC
-0.35-4.110-0.53
Return on tangible assets
-0.26-0.92-0.28-0.28
Graham Net
-0.54-1.124.462.62
Working capital
45.35M23.88M341.02M254.31M
Tangible asset value
-24.73M-51.56M336.17M260.32M
Net current asset value
-26.44M-54.49M328.29M200.78M
Invested capital
-0.1-0.1800.23
Average receivables
000456.5K
Average payables
0494K1.39M2.72M
Average inventory
0009.11M
Days sales outstanding
000435.61
Days payables outstanding
0001.43K
Days of inventory on hand
0008.43K
Receivables turnover
0000.84
Payables turnover
0000.25
Inventory turnover
0000.04
ROE
0.50.54-0.29-0.35
Capex per share
-0.02-0.030-0.08

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-09-302021-12-312022-03-312022-09-30 2022-12-31
Revenue per share
00000.01
Net income per share
-0.25-0.27-0.31-0.33-0.3
Operating cash flow per share
-0.150-0.28-0.31-0.28
Free cash flow per share
-0.180-0.29-0.32-0.31
Cash per share
4.984.74.453.73.44
Book value per share
4.914.664.473.893.66
Tangible book value per share
4.914.664.473.893.66
Share holders equity per share
4.914.664.473.893.66
Interest debt per share
0.140.140.230.830.83
Market cap
802.57M834.2M448.08M178.04M143.01M
Enterprise value
573.17M643.06M275.97M143.83M127.59M
P/E ratio
-11.39-10.55-5.09-1.87-1.69
Price to sales ratio
0000186.94
POCF ratio
-73.120-22.59-8.17-7.18
PFCF ratio
-63.710-21.57-7.77-6.58
P/B Ratio
2.282.481.410.640.55
PTB ratio
2.282.481.410.640.55
EV to sales
0000166.78
Enterprise value over EBITDA
-33.57-32.86-13.29-6.56-6.67
EV to operating cash flow
-52.220-13.91-6.6-6.41
EV to free cash flow
-45.50-13.28-6.28-5.87
Earnings yield
-0.02-0.02-0.05-0.13-0.15
Free cash flow yield
-0.020-0.05-0.13-0.15
Debt to equity
0.050.060.080.250.26
Debt to assets
0.050.050.070.20.21
Net debt to EBITDA
13.449.778.291.560.81
Current ratio
60.851.5735.8720.1819.01
Interest coverage
-74.62-102.46-155.07-117.03-92.72
Income quality
0.6200.90.920.94
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
000014.07
Intangibles to total assets
00000
Capex to operating cash flow
0.1500.050.050.09
Capex to revenue
0000-2.38
Capex to depreciation
-5.350-0.85-0.68-1.06
Stock based compensation to revenue
00004.05
Graham number
5.215.365.585.414.94
ROIC
0.160.40.57-0.16-0.13
Return on tangible assets
-0.05-0.06-0.06-0.07-0.06
Graham Net
4.724.434.152.872.62
Working capital
358.24M341.02M316.71M271.94M254.31M
Tangible asset value
352.07M336.17M317.48M276.93M260.32M
Net current asset value
345.46M328.29M301.16M217.56M200.78M
Invested capital
0.030.030.050.210.23
Average receivables
00347K0891K
Average payables
2.54M2.37M2.94M03.04M
Average inventory
003.16M017.46M
Days sales outstanding
0000107.41
Days payables outstanding
0000353.5
Days of inventory on hand
00002.08K
Receivables turnover
00000.84
Payables turnover
00000.25
Inventory turnover
00000.04
ROE
-0.05-0.06-0.07-0.09-0.08
Capex per share
-0.020-0.01-0.02-0.03

OMIC Frequently Asked Questions

What is Singular Genomics Systems, Inc. stock symbol ?

Singular Genomics Systems, Inc. is a US stock , located in La jolla of Ca and trading under the symbol OMIC

What is Singular Genomics Systems, Inc. stock quote today ?

Singular Genomics Systems, Inc. stock price is $1.21 today.

Is Singular Genomics Systems, Inc. stock public?

Yes, Singular Genomics Systems, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap